Drug Profile
Research programme: gene therapies - Adverum Biotechnologies/Synpromics
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Adverum Biotechnologies; Synpromics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders; Liver disorders
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Liver-disorders in USA
- 28 Jan 2020 No recent reports of development identified for research development in Eye-disorders in USA
- 13 Aug 2019 Synpromics has been acquired by Asklepios BioPharmaceutical